Seres Therapeutics Inc (MCRB) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Seres Therapeutics Inc   (NASDAQ: MCRB)


Seres Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Seres Therapeutics Inc 's ROA in the second quarter of 2026?
Seres Therapeutics Inc recorded a cumulative net loss of $-22 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -17.87%.

However, within the Healthcare sector 348 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 1640 to 3712.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -28.07 % -28.36 % 164.7 % 62.13 % -31.54 %
Y / Y Net Income Change - - - -90.76 % -
Net Income (TTM) in million -22 -47 6 5 86
Return On Assets (TTM) -17.87 % -34.54 % 3.86 % 4.28 % 76.64 %
MCRB's Total Ranking # 3712 # 1640 # 1441 # 71 # 114
Total Assets (TTM) in million 103 118 138 143 144
Seq. Total Assets Change -12.05 % -14.89 % -3.68 % -0.23 % -12.41 %
Seq. Net Income Change - - - - -

MCRB's 5 Years Annual ROA >> Back to MCRB Management Effectiveness >> Compare MCRB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 126
Sector # 349
Overall # 3386

Return On Assets Statistics
High Average Low
54.88 %
-36.67 %
-87.94 %
(Jun 30 2025)   (Mar 31 2023)



  News about Seres Therapeutics Inc Return on Assets ROA

Seres Therapeutics Finalizes VOWST Sale to Nestlé Health Science Amid Financial Losses, Focuses on Advancing Live Biotherapeutics Development,

In a landmark strategic move, Seres Therapeutics, Inc. (Nasdaq: MCRB), headquartered in Cambridge, Massachusetts, has successfully completed the sale of its VOWST business to Societé des Produits Nestlé S.A. a subsidiary of Nestlé Health Science. This decision comes as part of Seres’ broader strategy to align its resources on the development of its core offerings, particularly its promising live biotherapeutics targeting medically vulnerable populations at risk for life-threatening bacterial infections.On September 26, 2024, Seres Therapeutics reported that its stockholders overwhelmingly approved the sale of VOWST, following an announcement earlier in the month that indicated the transaction was forthcoming. This strategic divestment is expected to facilitate further development of SER-155 and other cultivated live biotherapeutics, targeting patient groups requiring advanced treatment options. The completion of this sale marks a critical juncture for Seres as it cultivates opportunities for future growth in the biotherapeutics sector.

Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science; Sale Expected to Close on September 30

Seres Therapeutics Gains Stockholder Endorsement for VOWST Sale to Nestlé Health Science, Anticipated Closure by Month-EndIn a strategic move that underscores the evolving landscape of biotherapeutics, Seres Therapeutics, Inc. (Nasdaq: MCRB), headquartered in Cambridge, Massachusetts, has announced the successful approval of its shareholders for the sale of its VOWST business to Société des Produits Nestlé S.A. a subsidiary of Nestlé Health Science. This pivotal decision marks a significant milestone in Seres’ corporate strategy and positions the company to optimize its resources and focus on its core competencies in live biotherapeutics.On September 26, 2024, Seres reported that the votes from its stockholders overwhelmingly supported the proposed transaction, which had been previously announced. As part of its commitment to transparency and adherence to regulatory requirements, Seres plans to file a Current Report on Form 8-K with the Securities and Exchange Commission (SEC). This filing will provide comprehensive details regarding the voting results and further clarify the implications of this major corporate decision.



Financial Statements
Seres Therapeutics Inc 's Assets $ 103 million MCRB's Balance sheet
Seres Therapeutics Inc 's Income $ 5 million Quarterly MCRB's Income Statement
MCRB's Income by Division See MCRB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 164.7 % -78.45 % 4.36 % -29.66 % -1.62 %
Total Assets in million 138 52 242 232 330
Y / Y Net Income Change 4088.24 % - - - -
Net Income in million 6 0 -114 -250 -66
Annual Return On Assets 4.12 % 0.26 % -46.94 % -107.76 % -19.87 %

MCRB's 5 Years Annual ROA >> Back to MCRB Management Effectiveness >> Compare MCRB ROA to its Competitors



Comment on MCRB's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 4.12 % compared to prior year, due to annual net income growth of 4088.24 % to $5.70 million, while value of Seres Therapeutics Inc 's overall assets grew just by 164.7 % to $138.19 million, compared to $138.19 a year before.


More Return On Assets Ratios
MCRB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MCRB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MCRB's Competitors
Subscribers only: Roa for Seres Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for MCRB's Customers

You may also want to know
MCRB's Roi MCRB's Inventory Turnover Ratio MCRB's Growth Rates MCRB's Dividend Comparisons
MCRB's Profitability Ratios MCRB's Asset Turnover Ratio MCRB's Dividend Growth
MCRB's Roe MCRB's Valuation Ratios MCRB's Financial Strength Ratios MCRB's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-10T16:17:22+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.